Trials / Completed
CompletedNCT01686620
A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)
A Randomized, Parallel Group Trial Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes Using Basal-bolus Insulin Injection Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Biodel · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIOD-123 | |
| DRUG | Lispro (Humalog) |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2012-09-18
- Last updated
- 2015-07-28
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01686620. Inclusion in this directory is not an endorsement.